TickerFiles

Acrivon Therapeutics, Inc. 10-K filing

Filed 2026-03-19 · Report date 2025-12-31 · 2025 FY

View Original SEC Filing

Filing metadata

Accession number
0001193125-26-115123
Form type
10-K
CIK
0001781174
Primary document
https://www.sec.gov/Archives/edgar/data/1781174/000119312526115123/acrv-20251231.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for Acrivon Therapeutics, Inc..

Reported financial metrics

MetricCurrentPriorChange
Operating Income$-84.1M--
Net Income$-77.9M--
Eps Basic-2.02--
Eps Diluted-2.02--
Cash And Equivalents$41.5M--
Total Assets$129.7M--
Total Liabilities$17.2M--
Shareholders Equity$112.5M--
Operating Cash Flow$-63.7M--
Capital Expenditures$1.7M--